March 23, 2023 03:23 PM EDT
Law

Pa­tients ap­peal NI­H's re­jec­tion to use 'march-in' rights on Astel­las' prostate can­cer drug Xtan­di

Paul Schloesser

Associate Editor

NIH de­clined to use “march-in” rights to low­er the price of Astel­las’ and Pfiz­er’s prostate can­cer drug Xtan­di ear­li­er this week, and now the pa­tients …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times